1. Home
  2. HALO vs PCVX Comparison

HALO vs PCVX Comparison

Compare HALO & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$82.90

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$54.63

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HALO
PCVX
Founded
1998
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
7.0B
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
HALO
PCVX
Price
$82.90
$54.63
Analyst Decision
Buy
Strong Buy
Analyst Count
11
4
Target Price
$78.64
$88.25
AVG Volume (30 Days)
1.7M
976.5K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.22
N/A
Revenue
$151,862,000.00
N/A
Revenue This Year
$28.24
N/A
Revenue Next Year
$12.56
N/A
P/E Ratio
$67.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.23
$29.10
52 Week High
$84.44
$65.00

Technical Indicators

Market Signals
Indicator
HALO
PCVX
Relative Strength Index (RSI) 63.84 N/A
Support Level $67.63 N/A
Resistance Level $84.44 N/A
Average True Range (ATR) 2.03 0.00
MACD 0.03 0.00
Stochastic Oscillator 76.24 0.00

Price Performance

Historical Comparison
HALO
PCVX

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: